查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1775524

特发性肺纤维化诊断与治疗市场－2025年至2030年的预测

Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

特发性肺纤维化诊断和治疗市场预计将从 2025 年的 59.17 亿美元成长到 2030 年的 85.49 亿美元，复合年增长率为 7.64%。

本研究报告对全球特发性肺纤维化 (IPF) 诊断和治疗市场进行了全面分析，为行业专业人士提供关于市场趋势、治疗进展以及影响这一重要医疗保健领域的竞争策略的重要见解。报告探讨了关键的市场动态，包括市场驱动因素、限制因素和机会，并按类型、药物类型、给药途径、最终用途和地区进行了详细细分。这项市场格局研究旨在辅助策略决策，为相关人员提供数据主导的预测、监管和竞争情报，帮助他们应对不断变化的 IPF 解决方案格局。

调查概述

特发性肺纤维化诊断与治疗市场研究报告按类型（诊断检测、药剂、治疗）、药物种类（Pirfenidone、尼达尼布等）、给药途径（口服、注射）、最终用途（医院/诊所、门诊手术中心等）和地区（北美、南美、欧洲、中东和非洲、亚太地区）对全球特发性肺纤维化 (IPF) 市场进行了研究。报告提供了包括波特五力分析、产业价值链分析和市场占有率评估在内的稳健分析，以及策略建议和监管见解，旨在帮助相关人员抓住这一重要市场的成长机会。

竞争格局与分析

特发性肺纤维化诊断和治疗市场研究的竞争情报部分重点介绍了主要企业为提升其市场占有率而采取的策略性倡议。例如，勃林格殷格翰最近透过扩大适应症的监管核准，扩展了其尼达尼布产品组合，增强了其在医院和诊所治疗特发性肺纤维化（IPF）中的应用。这项发展巩固了勃林格殷格翰在药理解决方案领域的领导地位。同样，FibroGen 正在透过策略合作推进其临床管线，开发用于早期发现特发性肺纤维化的新型诊断测试，旨在改善医疗保健领域的患者预后。该研究还包含市场占有率分析、併购以及竞争仪表板，以全面了解竞争格局。

结论

本研究报告是业内专业人士了解特发性肺纤维化 (IPF) 诊断和治疗市场复杂性的重要资源。透过提供详细的市场区隔、技术格局和竞争情报，本研究为识别机会和製定有效策略提供了坚实的框架。勃林格殷格翰和FibroGen, Inc.等领先公司正在推动药理学和诊断领域的技术创新，本市场研究将帮助相关人员在这个充满活力且快速发展的行业中保持竞争力。

本报告的主要优点

  • 深入分析：深入了解主要和新兴地区的市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局：了解主要企业采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力来提供策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业来说，都是有益且具有成本效益的。

它有什么用途？

产业与市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析（包括国家）
  • 公司概况（财务资讯、主要发展等）。

特发性肺纤维化诊断和治疗市场报告涵盖的各个细分市场包括：

按类型

  • 诊断测试
  • 药剂
  • 手术治疗

依药物类型

  • Pirfenidone
  • 尼达尼布
  • 其他的

依给药途径

  • 口服
  • 肠外

依使用目的

  • 医院和诊所
  • 门诊手术中心
  • 其他的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他中东和非洲地区
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印尼
  • 泰国
  • 其他的

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章特发性肺纤维化诊断与治疗市场（按类型）

  • 介绍
  • 诊断测试
  • 药理药物
  • 手术治疗

第六章特发性肺纤维化诊断与治疗市场（依药物类型）

  • 介绍
  • Pirfenidone
  • 尼达尼布
  • 其他的

第七章特发性肺纤维化诊断与治疗市场（依给药途径）

  • 介绍
  • 口服
  • 肠外

第八章特发性肺纤维化诊断和治疗市场（按最终用途）

  • 介绍
  • 医院和诊所
  • 门诊手术中心
  • 其他的

第九章特发性肺纤维化诊断与治疗市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 以色列
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章：公司简介

  • Roche Holding AG
  • Boehringer Ingelheim
  • AdAlta
  • FibroGen, Inc.
  • United Therapeutics
  • Galecto Biotech

第十二章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061610427

The Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market is expected to grow from USD 5.917 billion in 2025 to USD 8.549 billion in 2030, at a CAGR of 7.64%.

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study provides a comprehensive analysis of the global idiopathic pulmonary fibrosis (IPF) diagnostic and treatment market, offering industry experts critical insights into market trends, therapeutic advancements, and competitive strategies shaping this vital healthcare sector. This study explores key market dynamics, including drivers, restraints, and opportunities, with detailed segmentation by type, drug type, route of administration, end-use, and geography. Designed to support strategic decision-making, the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study equips stakeholders with data-driven forecasts, regulatory insights, and competitive intelligence to navigate the evolving landscape of IPF solutions.

Study Overview

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study examines the global IPF market, segmented by type (Diagnostic Testing, Pharmacological Drugs, Surgical Treatment), drug type (Pirfenidone, Nintedanib, Others), route of administration (Oral, Parenteral), end-use (Hospitals and Clinics, Ambulatory Surgical Centers, Others), and geography (North America, South America, Europe, Middle East and Africa, Asia Pacific). It includes robust analyses such as Porter's Five Forces Analysis, Industry Value Chain Analysis, and market share evaluations, alongside strategic recommendations and regulatory insights to help stakeholders capitalize on growth opportunities in this critical market.

Competitive Environment and Analysis

In the competitive intelligence section of the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study, key players are highlighted for their strategic initiatives to strengthen market presence. For instance, Boehringer Ingelheim has recently advanced its nintedanib portfolio by securing regulatory approvals for expanded indications, enhancing its application in IPF treatment across hospitals and clinics. This development reinforces Boehringer Ingelheim's leadership in pharmacological solutions. Similarly, FibroGen, Inc. has progressed its clinical pipeline through a strategic collaboration to develop novel diagnostic testing methods for early IPF detection, targeting improved patient outcomes in the healthcare sector. The study also covers market share analysis, mergers, acquisitions, and a competitive dashboard to provide a holistic view of the competitive landscape.

Conclusion

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study is an essential resource for industry experts seeking to understand the complexities of the IPF diagnostic and treatment market. By offering detailed segmentation, technological outlooks, and competitive intelligence, this study provides a robust framework for identifying opportunities and formulating effective strategies. With leading players like Boehringer Ingelheim and FibroGen, Inc. driving innovation in pharmacological and diagnostic advancements, the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study empowers stakeholders to stay competitive in this dynamic and rapidly evolving industry.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Different segments covered under the idiopathic pulmonary fibrosis diagnostic and treatment market report are as below:

By Type

  • Diagnostic Testing
  • Pharmacological Drugs
  • Surgical Treatment

By Drug Type

  • Pirfenidone
  • Nintedanib
  • Others

By Route of Administration

  • Oral
  • Parenteral

BY End-Use

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Diagnostic Testing
  • 5.3. Pharmacological Drugs
  • 5.4. Surgical Treatment

6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY DRUG TYPE

  • 6.1. Introduction
  • 6.2. Pirfenidone
  • 6.3. Nintedanib
  • 6.4. Others

7. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY END-USE

  • 8.1. Introduction
  • 8.2. Hospitals and Clinics
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Others

9. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East & Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. Israel
    • 9.5.3. UAE
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Roche Holding AG
  • 11.2. Boehringer Ingelheim
  • 11.3. AdAlta
  • 11.4. FibroGen, Inc.
  • 11.5. United Therapeutics
  • 11.6. Galecto Biotech

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key benefits for the stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations